Episode summary
OpenAI Misses Targets, Codex vs Claude, Elon vs Sam Trial, Big Hyperscaler Beats, Peptide Craze
All-In Podcast
· · 1 hr 21 min · Hosts: Chamath Palihapitiya, Jason Calacanis, David Sacks, David Friedberg
Summary
OpenAI’s latest week was framed as a public miss on users and revenue, even as the hosts argued the company may still be winning on product. The discussion centered on the Wall Street Journal report that OpenAI has not hit its 1 billion weekly active user goal or its 2025 revenue target, while carrying roughly $600 billion in compute commitments and facing pressure ahead of a possible IPO. One side argued the market is overreacting because OpenAI’s new coding model improvements are gaining traction just as coding becomes the most valuable AI use case.
The larger thesis was that AI demand is not the bottleneck; power and compute are. The hosts said hyperscalers like Google, Microsoft, Amazon, and Meta are benefiting from a huge capex cycle, while OpenAI and Anthropic are constrained by energy, grid, and supply-chain limits. They also discussed AI cybersecurity as a fast-growing market, arguing frontier models will soon help defenders find vulnerabilities as well as attackers.
The episode also covered Elon Musk’s lawsuit against Sam Altman and OpenAI, the risk of vibe-coding failures after an AI deleted a codebase, and the mainstreaming of peptide drugs like retatrutide as the next consumer craze.
Key takeaways
- OpenAI missed user and revenue targets, but the hosts think its product momentum in coding may be improving.
- The limiting factor in AI is power, not demand, which they say favors hyperscalers with the biggest infrastructure budgets.
- They believe AI cybersecurity is becoming a major new market because frontier models can both attack and defend codebases.
- The Musk-vs-Altman trial could matter most if it delays OpenAI’s IPO or forces a cap-table or structural reset.
- Retatrutide and similar peptide drugs are being treated as the next mainstream health trend with major consumer demand.
Notable quotes
“OpenAI has $600 billion in spending commitments for compute. Just to put that in perspective, that's about what they're trading for on secondary markets”
“It is entirely 100% due to the supply of the power necessary to generate the output token”
“the frontier models have reached the point where they're capable of automating cyber activities just like they're capable of automating coding”
“AI is now synonymous with the growth of the American economy”
How the episode opens
Jason, do you want to tell us about your new favorite podcast? Oh, it's so good. My feed is now because, you know, since cancel culture ended, Sachs, everybody uses the R word and the f word right now.
My entire feed on Instagram is either gay or down syndrome or bulldogs. It's one of those three. And then I stumbled upon the Miss Thing pod, Miss Thing.
And they do a bit called gay name, straight name. Here's gay name or straight name for David. This good news and bad news freeird.
Here we go.
Gay name or straight name? — David. — David to me is straight. — Okay. But he has my perfect body. It can be confusing because I'm kind of like, are you gay? And it's like, no, I just want to be you, David.
Totally. Well, it's so like the Michelangelo's David the male ideal. It's like incredible body kind of small. Sorry. — Yeah. — Oh, — It's a little rough. — What? — What are you watching there, Jal? — They basically nailed these two, but okay, keep going.
I don't think Chimoth is on their short list, but I know Jason will come up at some point. — Gay name or straight. — Maybe this is it. — Chimoth on the count of three. Yeah. — Three, two, one. gay. I'm seeing like Italian sweater, like really kind of like a loud vibrant sweater. He like wears it to like poker night with his like his boys and like not I'm not talking like straight poker. I'm talking like gay poker nights like at the bar.
Yeah. Always talking about wine. — Talks about wines. — Always sort of like Yeah, exactly. — Yep. Also, it's so like the guy at the gym taking off his shirt, taking selfies.
From the episode’s captions: roughly the first two minutes, lightly cleaned. Keep watching on YouTube →
Topics
- openai misses targets
- codex vs claude
- elon vs sam altman lawsuit
- hyperscaler capex earnings
- retatrutide peptides
Companies and tickers mentioned
- CSCO
- LLY
- OpenAI
- Anthropic
- Cisco Systems
- Eli Lilly and Company
Watch the episode
Summary, takeaways and quote selection by Octagon. Quotes are short excerpts; the full conversation is in the episode.
More from All-In Podcast
-
Jensen OUT as Nvidia CEO: "Spy" Scandal, Export Restrictions, Market Impact -
Freedom vs. Safety: Axon CEO Rick Smith on the Future of Policing -
Midterm Blood Bath, $4T AI Sell Off, Data Center Freeze, What’s Next for Trump -
All-In Podcast REACTS to Democrat Sweep! -
Anthropic S-1 Shocker, Greatest Business Ever? Google’s $500B Wipeout, Midterm Predictions -
WHOOP CEO, Will Ahmed: 50B Hours of Health Data, a 4 Million Member Data Moat, & the FDA Fight
All-In Podcast, this episode and its artwork belong to All-In Podcast, LLC. Octagon is not affiliated with the show; this page is an independent summary.
